SEC Filings

Filing Date

Form

Description

Downloads

9/25/15 10-Q Quarterly Report Download SEC Filing to Adobe PDF ico_xbrl
2/24/15 10-Q Quarterly Report Download SEC Filing to Adobe PDF  ico_xbrl
11/19/2014 10-Q Quarterly Report Download SEC Filing to Adobe PDF ico_xbrl
09/22/14 S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Download SEC Filing to Word Download SEC Filing to Adobe PDF  ico_xbrl
08/13/14 NT 10-Q Notification that Quarterly Report will be submitted late Download SEC Filing to Word Download SEC Filing to Adobe PDF  ico_xbrl
07/11/14 10-K Annual Report Download SEC Filing to Word Download SEC Filing to Adobe PDF  ico_xbrl
02/19/14 10-Q Quarterly report [Sections 13 or 15(d)] Acc-no: 0001255294-14-000095(34 Act) Download SEC Filing to Word Download SEC Filing to Adobe PDF ico_xbrl
11/19/13 10-Q Quarterly report [Sections 13 or 15(d)] Acc-no: 0001255294-13-000937 (34 Act) Download SEC Filing to Word Download SEC Filing to Adobe PDF ico_xbrl
08/19/13 10-Q Quarterly report [Sections 13 or 15(d)] Acc-no: 0001255294-13-000668 (34 Act) Download SEC Filing to Word Download SEC Filing to Adobe PDF ico_xbrl
07/01/13 10K 2013  Annual Report 2013 ico_xbrl

News

April 10th, 2018

Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
View Release

March 14th, 2018

Rich Pharmaceuticals’ Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin’s Lymphoma
View Release

March 6th, 2018

Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting Infections, and in Immunotherapy
View Release

» View All News

Stock Price